Revance Therapeutics (RVNC) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Revance Releases Second Quarter 2018 Results
August 2, 2018 4:05 PM EDTNEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2018.
Recent Company Highlights and Upcoming Milestones for DaxibotulinumtoxinA for Injection (RT002)
Revance expects to complete the SAKURA 3 open-label, long-term safety study of RT002 for the treatment of glabellar (frown) lines in the fourth quarter of 2018. The Company remains on track to file its Biologics Licensing Application (BLA) for RT002 to treat glabellar (frown) lines in first... More